Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025
Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on novel cancer therapies, has scheduled its fourth quarter and full year 2024 financial results announcement for Wednesday, February 19, 2025. The company will host a conference call and audio webcast at 8:00 a.m. ET on the same day.
Investors can access the conference call via phone at (800) 836-8184 (local) or (646) 357-8785 (international). The webcast and accompanying slides will be available in the Investor section of Karyopharm's website under 'Events & Presentations', with an archived version accessible approximately two hours after the event.
Karyopharm Therapeutics (Nasdaq: KPTI), un'azienda farmaceutica in fase commerciale focalizzata su terapie innovative per il cancro, ha programmato l'annuncio dei suoi risultati finanziari del quarto trimestre e dell'anno intero 2024 per mercoledì 19 febbraio 2025. L'azienda ospiterà una conferenza telefonica e un webcast audio alle 8:00 a.m. ET dello stesso giorno.
Gli investitori possono accedere alla conferenza telefonica tramite telefono al numero (800) 836-8184 (locale) o (646) 357-8785 (internazionale). Il webcast e le diapositive correlate saranno disponibili nella sezione Investitori del sito web di Karyopharm sotto 'Eventi e Presentazioni', con una versione archiviata accessibile circa due ore dopo l'evento.
Karyopharm Therapeutics (Nasdaq: KPTI), una empresa farmacéutica en etapa comercial centrada en terapias novedosas para el cáncer, ha programado el anuncio de sus resultados financieros del cuarto trimestre y del año completo 2024 para el miércoles 19 de febrero de 2025. La compañía llevará a cabo una conferencia telefónica y un webcast de audio a las 8:00 a.m. ET el mismo día.
Los inversores pueden acceder a la conferencia telefónica por teléfono al (800) 836-8184 (local) o al (646) 357-8785 (internacional). El webcast y las diapositivas acompañantes estarán disponibles en la sección de Inversores del sitio web de Karyopharm bajo 'Eventos y Presentaciones', con una versión archivada accesible aproximadamente dos horas después del evento.
Karyopharm Therapeutics (Nasdaq: KPTI)는 혁신적인 암 치료에 중점을 둔 상업 단계의 제약 회사로, 2024년 4분기 및 연간 재무 결과 발표를 2025년 2월 19일 수요일로 예정하고 있습니다. 회사는 같은 날 오전 8시(동부 표준시)에 전화 회의 및 오디오 웹캐스트를 개최할 예정입니다.
투자자는 (800) 836-8184(국내) 또는 (646) 357-8785(국제)로 전화 회의에 접속할 수 있습니다. 웹캐스트와 관련 슬라이드는 Karyopharm 웹사이트의 투자자 섹션 '이벤트 및 발표'에서 제공되며, 이벤트 후 약 2시간 후에 아카이브 버전이 접근 가능합니다.
Karyopharm Therapeutics (Nasdaq: KPTI), une entreprise pharmaceutique en phase commerciale axée sur des thérapies novatrices contre le cancer, a prévu l'annonce de ses résultats financiers du quatrième trimestre et de l'année 2024 pour le mercredi 19 février 2025. L'entreprise organisera une conférence téléphonique et un webinaire audio le même jour à 8h00 ET.
Les investisseurs peuvent accéder à la conférence téléphonique par téléphone au (800) 836-8184 (local) ou au (646) 357-8785 (international). Le webinaire et les diapositives associées seront disponibles dans la section Investisseurs du site de Karyopharm sous 'Événements & Présentations', avec une version archivée accessible environ deux heures après l'événement.
Karyopharm Therapeutics (Nasdaq: KPTI), ein Pharmaunternehmen in der kommerziellen Phase, das sich auf neuartige Krebstherapien konzentriert, hat die Bekanntgabe seiner Finanzergebnisse für das vierte Quartal und das gesamte Jahr 2024 für Mittwoch, den 19. Februar 2025 angesetzt. Das Unternehmen wird am selben Tag um 8:00 Uhr ET eine Telefonkonferenz und einen Audio-Webcast veranstalten.
Investoren können über das Telefon unter (800) 836-8184 (lokal) oder (646) 357-8785 (international) auf die Telefonkonferenz zugreifen. Der Webcast und die begleitenden Folien werden im Investorenbereich der Karyopharm-Website unter 'Veranstaltungen & Präsentationen' verfügbar sein, wobei eine archivierte Version etwa zwei Stunden nach der Veranstaltung zugänglich ist.
- None.
- None.
-- Conference Call Scheduled for Wednesday, February 19, 2025, at 8:00 a.m. ET --
To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeutics call. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations. An archived webcast will be available on the Company's website approximately two hours after the event.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the
XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-report-fourth-quarter-and-full-year-2024-financial-results-on-february-19-2025-302372912.html
SOURCE Karyopharm Therapeutics Inc.
FAQ
When will Karyopharm (KPTI) release Q4 and full year 2024 earnings?
What time is KPTI's Q4 2024 earnings call?
How can investors access KPTI's Q4 2024 earnings call?
Where can I find KPTI's Q4 2024 earnings presentation slides?
